Psychiatric Imaging
Lead Research Organisation:
MRC London Institute of Medical Sciences
Abstract
Psychotic illnesses such as schizophrenia are common and amongst the top ten greatest causes of adult disability in the world. We urgently need new and better treatments. However, a major limit on developing better treatments is that we don t understand what leads to psychosis. The brain chemical messenger, dopamine, is known to be abnormal in the condition. It is also known that cannabis use, and some forms of social stress, increase the risk of psychosis. We aim to study how these risk factors affect the dopamine system, and see if differences in dopamine function explain why some vulnerable people develop psychosis and others do not. We also know that current treatments act down-stream of the dopamine abnormality, but it is not clear whether they make this abnormality better or worse. We will test whether the dopamine system is different in patients who do not respond to treatment, and if treatment increases the dopamine abnormality. Finally we will also test whether we can counter the dopamine abnormality by targeting its control mechanisms. These studies will help predict and prevent psychosis, and develop better treatments.
Technical Summary
Psychotic disorders such as schizophrenia are amongst the top ten causes of disability in adults- accounting for one in every ten hospital beds used in the UK. The main treatments, the antipsychotic drugs, were discovered over fifty years ago. Since then there has been limited progress as: i) the medications are still based on the same old principle (dopamine (DA) receptor blockade), ii) there are no good predictors of response so treatment proceeds by trial-and-error, and iii) current treatments are ineffective for one in three patients. A major limit for the development of new, rational treatments has been the lack of a defined etiology and limited knowledge of the pathophysiology of schizophrenia. As a result most drug development in the last fifty years has simply sought to emulate aspects of existing antipsychotics and/or has used empirical animal models (e.g.: conditioned avoidance response or PCP-induced locomotion) that were developed prior to clear knowledge of the pathophysiology.|However, there is now evidence of a defined neurochemical pathophysiology in psychosis. Over fifteen in vivo studies in the last decade point to one central fact: presynaptic DA dysfunction is the final common pathway leading to psychosis (data reviewed and synthesized in: Howes et al, B J Psuch, 2007 & Lyon et al. Schiz. Bull. doi:10.1093, 2009). For this reason understanding the causes and implications of presynaptic DA dysfunction is critical to the pathophysiology of psychosis and provides a framework for understanding risk factors, predicting onset and delivering new treatments as set out in a recent review of the area (Howes and Kapur, Schiz Bulletin, 2009). The programme is divided into four sections: (a) Risk factors to pathophysiology; (b) Predicting illness onset; (c) Pathophysiology to therapeutics; (d) Targets beyond dopamine.|The first section will investigate the effects of the two major environmental risk factors for psychosis - cannabis use and social stress/defeat - on DA function using F-DOPA and raclopride positron emission tomography (PET) in individuals exposed to these risk factors. Section 2 addresses the ultimate aim in therapeutics of psychosis - predicting and preventing its onset using PET and magnetic resonance imaging (MRI) to identify biomarkers and pathoetiological changes underlying the development of psychosis. One third of patients with established psychosis fail to respond to treatment. Section 3 will investigate the determinants and predictors of treatment response using PET and MR spectroscopy of dopamine and glutamate markers respectively. Section 4 investigates upstream modulators of DA to identify novel non-D2 targets for drug discovery using agents that act at DA autoreceptors and glutamatergic and other regulatory mechanisms.|These studies have the potential to identify prognostic markers for psychosis and new therapeutic avenues to treat established illness.|
Organisations
- MRC London Institute of Medical Sciences, United Kingdom (Lead Research Organisation)
- University of Oxford, United Kingdom (Collaboration)
- University College London, United Kingdom (Collaboration)
- University of Turku, Finland (Collaboration)
- Brain & Behaviour Research Foundation (Collaboration)
- University of Edinburgh, United Kingdom (Collaboration)
- Ludwig Maximilians University Munich (Collaboration)
- University Medical Centre Utrecht, Netherlands (Collaboration)
- University of Amsterdam (Collaboration)
- Koninklijke Philips Electronics N.V. (Collaboration)
- Autonomous University of Madrid, Spain (Collaboration)
- Cardiff University, United Kingdom (Collaboration)
- AstraZeneca plc (Collaboration)
- University of Helsinki, Finland (Collaboration)
- Imanova (Collaboration)
- University of Queensland, Australia (Collaboration)
- F. Hoffmann-La Roche AG (Collaboration)
- Sylics (Collaboration)
- Heinrich Heine University Düsseldorf (Collaboration)
- King's College London, United Kingdom (Collaboration)
People |
ORCID iD |
Oliver Howes (Principal Investigator) |
Publications

Adams RA
(2020)
Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models.
in Cerebral cortex (New York, N.Y. : 1991)

Allen P
(2012)
Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis.
in Schizophrenia bulletin

Allen P
(2016)
Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis.
in The American journal of psychiatry

Allen P
(2018)
Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort.
in Schizophrenia bulletin

Allen P
(2015)
Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation.
in Schizophrenia bulletin

Allen P
(2012)
Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals.
in Schizophrenia bulletin

Arnone D
(2018)
The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram.
in Progress in neuro-psychopharmacology & biological psychiatry

Ashok AH
(2017)
The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment.
in Molecular psychiatry

Ashok AH
(2019)
Tobacco smoking and dopaminergic function in humans: a meta-analysis of molecular imaging studies.
in Psychopharmacology
Description | Royal College Schizophrenia Treatment UK Guidelines |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
Impact | Management guidelines to all UK psychiatrists |
Description | Academy of Medical Sciences starter grant (emotion processing CUMI) |
Amount | £22,500 (GBP) |
Organisation | Academy of Medical Sciences (AMS) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2012 |
End | 06/2013 |
Description | Astra Zeneca Investigator Initiated Research |
Amount | £54,000 (GBP) |
Organisation | AstraZeneca |
Sector | Private |
Country | United Kingdom |
Start | 01/2016 |
End | 01/2017 |
Description | BMA Margaret Temple award for schizophrenia research |
Amount | £50,000 (GBP) |
Organisation | British Medical Association (BMA) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2015 |
End | 12/2017 |
Description | Banco di Sardegna Foundation project grant |
Amount | € 32,000 (EUR) |
Organisation | Fondazione Banco di Sardegna |
Sector | Charity/Non Profit |
Country | Italy |
Start | 08/2011 |
End | 09/2012 |
Description | Brain |
Amount | £1,000 (GBP) |
Organisation | Guarantors of Brain |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2009 |
End | 06/2009 |
Description | ECNP |
Amount | £1,000 (GBP) |
Organisation | European College of Neuropsychopharmacology (ECNP) |
Sector | Charity/Non Profit |
Country | Netherlands |
Start | 08/2009 |
End | 10/2009 |
Description | EU FP-7 |
Amount | € 3,838,000 (EUR) |
Organisation | European Union |
Sector | Public |
Country | European Union (EU) |
Start | 01/2013 |
End | 02/2018 |
Description | EU Marie Curie Fellowship- Alice Petty |
Amount | £224,781 (GBP) |
Organisation | European Union |
Sector | Public |
Country | European Union (EU) |
Start | 11/2021 |
End | 11/2023 |
Description | EU Marie Curie Fellowship- Garzia Rutigliano |
Amount | £326,371 (GBP) |
Organisation | European Union |
Sector | Public |
Country | European Union (EU) |
Start | 08/2021 |
End | 08/2023 |
Description | EU Marie-Curie |
Amount | € 330,000 (EUR) |
Organisation | European Union |
Sector | Public |
Country | European Union (EU) |
Start | 06/2013 |
End | 08/2017 |
Description | Independent Investigators Scheme (NARSAD) |
Amount | $96,000 (USD) |
Organisation | Brain & Behaviour Research Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 07/2013 |
End | 09/2015 |
Description | Investigator Grant |
Amount | £124,000 (GBP) |
Organisation | Autifony Therapeutics |
Sector | Private |
Country | United Kingdom |
Start | 06/2018 |
End | 07/2020 |
Description | King's India scholarship |
Amount | £107,771 (GBP) |
Organisation | King's College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2016 |
End | 05/2019 |
Description | MRC |
Amount | £350,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2008 |
End | 08/2010 |
Description | MRC Experimental Medicine Challenge Scheme |
Amount | £1,100,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2016 |
End | 07/2019 |
Description | March of Dimes |
Amount | £340,000 (GBP) |
Organisation | March of Dimes Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 12/2011 |
End | 12/2014 |
Description | Maudsley Charity TREAT Project grant |
Amount | £297,000 (GBP) |
Funding ID | 666 |
Organisation | South London and Maudsley (SLAM) NHS Foundation Trust |
Department | Maudsley Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2012 |
End | 12/2015 |
Description | NIHR |
Amount | £11,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 11/2011 |
End | 03/2012 |
Description | NIHR BRC starter grant (apo) |
Amount | £16,000 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Comprehensive Biomedical Research Centre, Guy's and St Thomas |
Sector | Public |
Country | United Kingdom |
Start | 11/2012 |
End | 11/2013 |
Description | Roche Investigator Initiated Research |
Amount | £254,000 (GBP) |
Organisation | F. Hoffmann-La Roche AG |
Sector | Private |
Country | Global |
Start | 01/2015 |
End | 12/2016 |
Description | Roche investigator initiated grant |
Amount | £72,000 (GBP) |
Organisation | F. Hoffmann-La Roche AG |
Sector | Private |
Country | Global |
Start | 03/2017 |
End | 04/2018 |
Description | Stratified Medicince |
Amount | £3,800,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2014 |
End | 06/2019 |
Description | Sunovion Investigator Initiated Grant |
Amount | £150,000 (GBP) |
Organisation | Sunovion Pharmaceuticals, Inc. |
Sector | Private |
Country | United States |
Start | 12/2016 |
End | 12/2018 |
Description | Wellcome |
Amount | £350,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2013 |
End | 02/2016 |
Description | Wellcome |
Amount | £1,054,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2011 |
End | 10/2016 |
Description | Wellcome Trust Clinical Research Training fellowship |
Amount | £356,554 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2015 |
End | 12/2019 |
Title | Antipsychotic decision aid tool |
Description | Tool to help patients make decisions about treatment |
Type Of Material | Model of mechanisms or symptoms - human |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | Taken up for use in the NHS |
Title | Database of neurochemical function in healthy volunteers |
Description | Database of PET imaging data on the dopaminergic and serotinergic systems in healthy volunteers and socio-demographic and psychological indices. |
Type Of Material | Biological samples |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | This has resulted in a number of publications describing the relationship between socio-demographic (including age, and substance misuse) and personality factors, and is being used by an EU consortium to develop novel approaches to PET image analysis |
Title | Dopamine imaging to predict treatment response in psychiatry |
Description | Method to guide clinical choice of treatment for patients with psychotic and other disorders |
Type Of Material | Physiological assessment or outcome measure |
Year Produced | 2020 |
Provided To Others? | No |
Impact | Patent |
Title | NODE PET |
Description | Database of PET and other imaging data and repository for data sharing and pooling |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | Combined analyses resulting in new publications |
Description | Cannabis, ketamine and psychosis (UCL) |
Organisation | University College London |
Department | Division of Psychology & Language Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We conducted imaging |
Collaborator Contribution | Our partners recruited subjects |
Impact | Publications- Freeman et al 2012 and others in submission |
Start Year | 2010 |
Description | EDiPs- dopamine in murine model of dopamine dysfunction |
Organisation | University of Queensland |
Country | Australia |
Sector | Academic/University |
PI Contribution | we are contributing imaging technology |
Collaborator Contribution | University of Brisbane, Australia- contributing mice; |
Impact | On going investigations |
Start Year | 2018 |
Description | Genetics of neuropsychiatric disorders- Cardiff Uni collaboration |
Organisation | Cardiff University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We contributed new methodological approaches |
Collaborator Contribution | Access to data and expertise |
Impact | New analyses |
Start Year | 2021 |
Description | Hallucinators study |
Organisation | University Medical Center Utrecht (UMC) |
Department | Department of Psychiatry |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | Acquiring and analysing data |
Collaborator Contribution | Provision of a unique cohort of subjects, contributing towards the costs of the study and funding research workers to conduct the study |
Impact | Publications in preparation |
Start Year | 2010 |
Description | Imanova PDE |
Organisation | Imanova |
Country | United Kingdom |
Sector | Private |
PI Contribution | Undertaking recruitment and measures in clinical population |
Collaborator Contribution | Development and provision of PET tracer |
Impact | Work in progress |
Start Year | 2012 |
Description | In-SENS |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | Brain & Behaviour Research Foundation |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | F. Hoffmann-La Roche AG |
Country | Global |
Sector | Private |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | Heinrich Heine University Düsseldorf |
Country | Germany |
Sector | Academic/University |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
Country | Germany |
Sector | Academic/University |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | Sylics |
Country | Netherlands |
Sector | Private |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | University of Amsterdam |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | University of Edinburgh |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | In-SENS |
Organisation | University of Helsinki |
Country | Finland |
Sector | Academic/University |
PI Contribution | Teaching and training and sharing data |
Collaborator Contribution | Teaching and training and sharing data |
Impact | Increased cadre of researchers with clinical translation skills |
Start Year | 2013 |
Description | METSY |
Organisation | Autonomous University of Madrid |
Country | Spain |
Sector | Academic/University |
PI Contribution | Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction |
Collaborator Contribution | Sharing data and expertise on analysis |
Impact | Harmonisation of data collection |
Start Year | 2013 |
Description | METSY |
Organisation | Koninklijke Philips Electronics N.V. |
Department | Philips |
Country | Global |
Sector | Private |
PI Contribution | Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction |
Collaborator Contribution | Sharing data and expertise on analysis |
Impact | Harmonisation of data collection |
Start Year | 2013 |
Description | METSY |
Organisation | University of Helsinki |
Country | Finland |
Sector | Academic/University |
PI Contribution | Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction |
Collaborator Contribution | Sharing data and expertise on analysis |
Impact | Harmonisation of data collection |
Start Year | 2013 |
Description | METSY |
Organisation | University of Turku |
Country | Finland |
Sector | Academic/University |
PI Contribution | Sharing data and collaborating on developing a new diagnostic and predictive biomarker platform for psychosis and metabolic dysfunction |
Collaborator Contribution | Sharing data and expertise on analysis |
Impact | Harmonisation of data collection |
Start Year | 2013 |
Description | Mood and cognition |
Organisation | University College London |
Department | Institute of Cognitive Neuroscience |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have undertaken the imaging side of the study |
Collaborator Contribution | Our partners have undertaken the behavioural testing |
Impact | Publications- Selvaraj et al Mol Psych 2012 and others in submission |
Start Year | 2011 |
Description | Neurobiology of affect regulation-brain-gene (Oxford) |
Organisation | University of Oxford |
Department | Department of Psychiatry |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Acquisition and analysis of neuroimaging data |
Collaborator Contribution | Determination of genetic polymorphisms and analysis of data & research fellow support |
Impact | Publications: Decreased regional gray matter volume in S' allele carriers of the 5-HTTLPR triallelic polymorphism. Selvaraj S, Godlewska BR, Norbury R, Bose S, Turkheimer F, Stokes P, Rhodes R, Howes O, Cowen PJ. Mol Psychiatry. 2010 Nov 2 |
Start Year | 2014 |
Description | Psychosis CAG |
Organisation | King's College London |
Department | Institute of Psychiatry, Psychology & Neuroscience |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | PET imaging of patients with schizophrenia and healthy volunteers |
Collaborator Contribution | Provision of unique clinical cohorts Funding of research fellows |
Impact | Publications: Delusional ideation, manic symptomatology and working memory in a cohort at clinical high-risk for psychosis: A longitudinal study. Broome MR, Day F, Valli I, Valmaggia L, Johns LC, Howes O, Garety P, McGuire PK. Eur Psychiatry. 2010 Oct 8. [Epub ahead of print] PMID: 20934858 [PubMed - as supplied by publisher] Related citations 3. A comprehensive review and model of putative prodromal features of bipolar affective disorder. Howes OD, Lim S, Theologos G, Yung AR, Goodwin GM, McGuire P. Psychol Med. 2010 Sep 14:1-11. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, O'Gorman RL, McLean MA, Barker GJ, McGuire P. Biol Psychiatry. 2010 Oct 1;68(7):599-602. Epub 2010 Jul 17. PMID: 20638047 [PubMed - in process] Related citations 6. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK. Arch Gen Psychiatry. 2010 Jul;67(7):683-91. PMID: 20603449 The dopamine hypothesis of schizophrenia: version III--the final common pathway. Howes OD, Kapur S. Schizophr Bull. 2009 May;35(3):549-62. Epub 2009 Mar 26. Review. PMID: 19325164 [PubMed - indexed for MEDLINE]Free PMC ArticleFree text Related citations 22. Functionally defined regions may aid interpretation of striatal dopamine elevation in schizophrenia. Egerton A, McGuire PK, Howes OD. Schizophr Res. 2009 Apr;109(1-3):200. Epub 2009 Feb 27. No abstract available. PMID: 19250801 [PubMed - indexed for MEDLINE] Related citations 23. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM. Arch Gen Psychiatry. 2009 Jan;66(1):13-20.PMID: 1912468 Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P. Mol Psychiatry. 2009 Dec 1 PMID: 19949389 |
Start Year | 2006 |
Title | Dopamine imaging to predict treatment response in psychiatry |
Description | Use of machine learning and novel imaging methods to guide treatment resposne |
IP Reference | tbc |
Protection | Patent application published |
Year Protection Granted | 2019 |
Licensed | No |
Impact | tbd |
Title | PET diagnostic classifier for schizophrenia |
Description | Multivariate image analytic system for diagnosing schizophrenia. The initial evaluation has been published and it is currently under refinement using additional clinical populations to determine its generalisability |
Type | Diagnostic Tool - Imaging |
Current Stage Of Development | Refinement. Clinical |
Year Development Stage Completed | 2010 |
Development Status | Under active development/distribution |
Impact | It has provide insights into the pathophysiology of schizophrenia |
Description | 2017 BBC Horizon Program entitled 'Why did I go Mad?' |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | BBC2 Film interview: Discussed how an excess of brain chemical dopamine can lead to paranoia and delusions. |
Year(s) Of Engagement Activity | 2017 |
Description | 2018 An image from my research has been published on Biomedical Picture of the day (BPoD) for International Women's Day 2018. http://bpod.mrc.ac.uk/archive/2018/3/8 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Other audiences |
Results and Impact | Biomedical Picture of the day (BPoD) for International Women's Day 2018. |
Year(s) Of Engagement Activity | 2018 |
Description | British Association of Psychopharmacology (BAP) conference in Harrogate in July 2017 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Guarantors of Brain Travel Award to attend British Association of Psychopharmacology (BAP) conference in Harrogate in July 2017 |
Year(s) Of Engagement Activity | 2017 |
Description | British Association of Psychopharmacology Travel bursary (£275) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | British Association of Psychopharmacology Travel bursary (£275) |
Year(s) Of Engagement Activity | 2017 |
Description | Central St Martin's College |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Primary Audience | Public/other audiences |
Results and Impact | Presentation to ~80 art students who will develop a project based on this as part of their course work Students producing art outputs as a result |
Year(s) Of Engagement Activity | 2010 |
Description | Guarantor's Brain Travel award to attend European Congress of Neuropsychopharmacology (£550) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Guarantor's Brain Travel award to attend European Congress of Neuropsychopharmacology (£550) |
Year(s) Of Engagement Activity | 2017 |
Description | Hearts and Minds event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Workshop on our research |
Year(s) Of Engagement Activity | 2016 |
Description | MRC Central St Martin's Art Science Initiative |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | I gave a talk and supervised three arts projects based on our scientific work. This led to a public exhibition in London. |
Year(s) Of Engagement Activity | 2019 |
Description | Media interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Interviews for BBC and National Geographic TV channels discussing the group's research findings Viewing figures are reported to be over 1 million for the BBC. The National Geographic broadcast is international as well as UK. |
Year(s) Of Engagement Activity | 2009,2010 |
Description | Media interviews on our research (The Guardian full page article 2017) |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | The Guardian: full page article on our IRIS study- picked up and reported by many other news outlets |
Year(s) Of Engagement Activity | 2017 |
Description | Media interviews with national news on our synaptic imaging projects |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | I gave media interviews about our recent work, resulting in at least articles in national and international newspapers and websites (including The Guardian and The Independent). This has resulted in many follow-up enquiries about our research from the public and health care professionals |
Year(s) Of Engagement Activity | 2020 |
Description | Patient publication |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Article in national patient and carer magazine (readership 50 000+) Patient and carers contacted me for further information |
Year(s) Of Engagement Activity | 2007 |
Description | Prize for presenting PhD Flask Talk at the MRC LMS Annual Retreat 2017. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Prize for presenting PhD Flask Talk at the MRC LMS Annual Retreat 2017. |
Year(s) Of Engagement Activity | 2017 |
Description | RCPsych patient & carer education |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Web cast informing carers and patients about sexual dysfunction in schizophrenia and treatment options. Patient and carer groups highlighted improved understanding of under-recognised aspect of the condition |
Year(s) Of Engagement Activity | 2012 |
Description | Radio and TV interviews on our research |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Interviews on BBC and newspapers (including Radio 4: All in the mind: interview on our research with Claudia Hammond 2018: Radio 4: Future Proofing: interview on future of mental health with Leo Johnson) |
Year(s) Of Engagement Activity | 2018 |